GlobalData’s report assesses the drugs in the Alpha Synuclein pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline.

From these initial locations, the progression of the disease is characterized by accumulations of a protein known as alpha-synuclein, which spreads in a predictable pattern. Sign up for Chip Chick’s ...

ATH434 shows promise as a disease-modifying therapy for MSA -- ATH434-202 Phase 2 interim data demonstrate stabilization of clinical symptoms ...

In this GEN webinar, our expert speaker, Dr. Sterling Johnson, will discuss multi-plex blood biomarker assays, new discoveries in AD research from a large-scale study, and opportunities for early ...

From biochemist to executive supplier to angel investor to company founder and CEO, Maria Maccecchini, Ph.D.’s ...

Andrew Fein, an analyst from H.C. Wainwright, maintained the Buy rating on Prothena (PRTA – Research Report). The associated price target ...

A question and answer session with Prof Suzanne Timmons, Professor of Geriatric Medicine at University College Cork ...

A forensic review led by neuroscientist Matthew Schrag, image analyst Kevin Patrick, and others identified issues in 132 ...

One of the major breakthroughs over the last couple of years has been a potential new diagnostic test for Parkinson’s – a ...

Annovis Bio saw promising results for Buntanetap in treating Alzheimer's and Parkinson's, but short cash runway prompts a ...

NIH started its research misconduct review process in May 2023 after it received allegations from the HHS Office of Research ...